Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants

Completed · Phase 3

Conditions studied: Anemia Associated With End Stage Renal Disease (ESRD)

In brief

The purpose of this study is to assess the safety and effectiveness of Roxadustat dosing regimens among chronic dialysis participants converted from ESA therapy or who are ESA-naïve.

Key facts

Study ID

NCT04410198

Run by

Kyntra Bio

People needed

203

Starts

2020-05-26

Expected to finish

2021-10-11

Last updated by the study team

2022-09-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Investigational Site — Englewood, Colorado, United States
• Investigational Site — Caldwell, Idaho, United States
• Investigational Site — Baton Rouge, Louisiana, United States
• Investigational Site — Kalamazoo, Michigan, United States
• Investigational Site — Tupelo, Mississippi, United States
• Investigational Site — Saint Ann, Missouri, United States
• Investigational Site — Las Vegas, Nevada, United States
• Investigational Site — Sugar Land, Texas, United States
• Investigational Site — St. George, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.